Hybridon is an industry leader in synthetic DNA , second generation antisense and its products are being used by several cos in current clinical trials . Eg Aegeras XIAP trial in the UK .
Cheers
'SOLBEC AGREEMENT WITH HYBRIDON INC.
Summary:
• Solbec has signed a material transfer agreement with Hybridon Inc. that covers the supply
of a synthetic TLR9 agonist from Hybridon for use in further pre-clinical evaluation.
Perth, 20 December 2004: Solbec Pharmaceuticals Ltd (ASX:SBP) announced today that it has
signed a Material Transfer Agreement with Hybridon Inc. of Cambridge, Massachusetts. The
agreement gives Solbec access to one of Hybridon’s Immunomodulatory Oligonucleotide
(IMO™) agonists of Toll-like receptor 9 (TLR9) that will be used in combination with Solbec’s
Coramsine™ for pre-clinical evaluation.
The forthcoming study will be carried out by the Tumour Immunology Group at the University of
Western Australia and will evaluate combinational immunotherapy in the treatment of malignant
mesothelioma and melanoma.
The evaluation is intended to confirm and extend the findings of a study, announced to the ASX
on 23rd November 2004, and is an essential step in preparing for an initial clinical trial of
combination therapy in patients.
Further information:
About Solbec
Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of
better therapies for debilitating conditions and life-threatening diseases. The company is currently
progressing its key project, Coramsine™, through Phase I/IIA clinical trials for the treatment of
mesothelioma and malignant melanoma, and as a topical treatment for psoriasis. Solbec's two proprietary
ingredients in Coramsine™ were isolated from the fruit of a weed known as the Devil’s Apple (Solanum
linnaeanum). They show activity against some cancers and cause potentially therapeutic changes to the
immune system. In addition to human health, Coramsine™ has potential application in the areas of animal
health and diagnostics. Solbec’s business strategy is to partner or out-license Coramsine™ for the final
stages of pre-commercial development and marketing.
About Hybridon Inc.
Hybridon, Inc. is engaged in the discovery, development, and commercialization of novel therapeutics
based on synthetic DNA for the treatment of cancer, asthma/allergies, and infectious diseases. Hybridon’s
drug candidates are designed to modulate immune responses through Toll-like receptor 9 and antisense and
are based on innovative DNA chemistries developed at Hybridon.
The Agreement
The Material Transfer Agreement has been negotiated under standard commercial terms to provide access
to Hybridon IMO™ materials for the purposes of pre-clinical evaluation of combination therapy with
Coramsine.
Solbec supports the principles contained in the working draft ASX & Ausbiotech Code of Best
Practice for Reporting by Biotechnology, Medical Device and other Life Sciences Companies.
Information contained in this communication is in accord with the Code.
For further information, please contact
Stephen Carter
Managing Director
Solbec Pharmaceuticals Ltd
Australia
Phone +61 (08) 944 67555
www.solbec.com.au
Tim Sullivan, Ph.D.
V.P Development Programs
Hybridon, Inc.
USA
Telephone: +1 (617) 679-5500
www.hybridon.com
Media:
Rebecca Christie
Phone: +61 (02) 9237 2800 / 0417 382 391
[email protected]
SBP
solbec pharmaceuticals limited
Hybridon is an industry leader in synthetic DNA , second...
Add to My Watchlist
What is My Watchlist?